http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2116388-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5929f2d6f4dba84be8dd3a8ba633db12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2f4521a4a491a92c33ab1aea2d13581
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-28
filingDate 1994-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6776b7af68de91214faf69514fafab28
publicationDate 1994-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2116388-A1
titleOfInvention Treatment for viral diseases
abstract An angiotensin II antagonist compound is administered to mammals with viral disease. This administration ameliorates virus-associated cell injuries, producing therapeutic effects in viral diseases. This compound is also useful for the prevention of such diseases. The angiotensin II antagonist compound is, for instance, of the formula: (see formula I) or a pharmacologically acceptable salt thereof, wherein the ring is a benzimidazole ring which may be substituted, R3 is a group capable of forming or transformable to an anion, X is a bond or a spacer of a chain having up to 2 atoms and n is 1 or 2.
priorityDate 1993-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457492341

Total number of triples: 30.